ClinicalTrials.gg

Program

fanregratinib

Also written as “HMPL-453”, “HMPL-453 with Itraconazole” and “HMPL-453 with Rifampin”.

Its studies are mostly in Cholangiocarcinoma · Stomach Neoplasms · Mesothelioma, Malignant, led by HUTCHMED.

Furthest: phase 3, since Apr 16, 20208 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HUTCHMED81 open or runningphase 3since Apr 16, 2020Oct 27, 2016Jun 30, 2028phase 3 · NCT04353375

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2016First study: phase 1 study in Solid TumorFirst studyNCT02966171 · 14 enrolled · Australia
  2. May 17, 2017Phase 2 study in Solid Tumor, AdultNCT03160833 · 33 enrolled · China
  3. Jan 17, 2020Phase 2 study in Advanced Malignant MesotheliomaNCT04290325 · 27 enrolled · China
  4. Apr 16, 2020Phase 3 study in Advanced Intrahepatic CholangiocarcinomaNCT04353375 · 235 planned · China
  5. Oct 31, 2021Phase 2 study in Stomach NeoplasmsNCT05173142 · 190 enrolled · China
  6. May 22, 2023Phase 1 study in CholangiocarcinomaNCT05930119 · 24 enrolled · China
  7. Feb 17, 2025Phase 1 study in Mass Balance StudyNCT07644442 · 6 enrolled · China
  8. Mar 5, 2025Phase 1 study in Health, SubjectiveNCT07697157 · 40 enrolled · China

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Advanced Intrahepatic CholangiocarcinomaNCT04353375

TargetBeta

FGFR1 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule

Other programs on FGFR1

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07697157Health, Subjective · China1CompletedDec 31, 202540
NCT07644442Mass Balance Study · China1CompletedMar 14, 20256
NCT05930119Cholangiocarcinoma · China1CompletedAug 28, 202324
NCT05173142Stomach Neoplasms · China2CompletedJul 17, 2025190
NCT04353375Advanced Intrahepatic Cholangiocarcinoma · China3RecruitingJun 30, 2028235
NCT04290325Advanced Malignant Mesothelioma · China2UNKNOWNNov 30, 202227
NCT03160833Solid Tumor, Adult · China2UNKNOWNDec 31, 201933
NCT02966171Solid Tumor · Australia1TerminatedAug 23, 201814

How it is read

Names in the registry

  • “HMPL-453”, 7 entries
  • “HMPL-453 with Itraconazole”, 1 entry
  • “HMPL-453 with Rifampin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.